? XILIO THERAPEUTICS (NASDAQ: XLO)
Immuno-Oncology | Tumor-Activated Therapies | Q3 2025 Report
? Executive Summary
Xilio Therapeutics, Inc. (NASDAQ: XLO) is a clinical-stage biopharmaceutical company pioneering the development of masked tumor-activated immunotherapies — a novel approach designed to activate immune responses exclusively within the tumor microenvironment, thereby minimizing systemic toxicity. The company’s lead candidate, vilastobart (anti-CTLA-4 tumor-activated antibody), has demonstrated exceptional clinical efficacy with a 40% objective response rate (ORR) in patients with microsatellite-stable metastatic colorectal cancer (MSS mCRC) — a historically difficult-to-treat indication with limited immunotherapy options.
Over the past 12 months, Xilio has achieved multiple inflection points. In February 2025, the company secured a landmark partnership with AbbVie worth $52 million upfront plus up to $2.1 billion in milestone payments, validating its masked T cell engager platform. Simultaneously, the vilastobart Phase 2 program showed remarkable clinical progression — ORR improved from 27% (January 2025) to 40% (November 2025) when enriched for plasma TMB-high patients without liver metastases, positioning the asset as potentially best-in-class for this indication.
Key Highlights:
- 40% ORR in MSS mCRC — 11 of 27 patients achieved partial or complete response with durable responses lasting up to 37 weeks and significant ctDNA reduction
- Favorable safety profile — Only 7% colitis incidence vs 20%+ reported for other anti-CTLA-4 agents, enabling better tolerability
- $2.1B partnership with AbbVie — Covers 3 masked T cell engager programs (PSMA, CLDN18.2, STEAP1) with significant non-dilutive funding
- Strong cash position — $103.8M cash with runway to Q1 2027, eliminating near-term financing risk
- Expanding partnerships — Gilead collaboration on XTX301 (IL-12), Roche collaboration on vilastobart + atezolizumab combination
- Revenue growth — Q3 2025 revenue $19.1M (+745% YoY) driven by partnership milestones from AbbVie and Gilead
However, Xilio remains a high-risk, high-reward microcap biotech. The stock trades at all-time lows (~$0.75) despite compelling clinical data, reflecting market skepticism regarding execution risk, cash runway beyond 2027, and competitive dynamics in immuno-oncology. The June 2025 equity raise resulted in a 27% stock decline, signaling dilution concerns. Analyst consensus price target stands at $3.00 (+300% upside), but achieving this would require successful Phase 2 data readouts, partnership milestone achievements, and sustained clinical momentum through 2026-2027.
Current Price: ~$0.75
Consensus Target: $3.00 (+300%)
Cash on Hand: $103.8M
Cash Runway: Q1 2027
? 12-Month Timeline: Key Events & Stock Catalysts
November 8, 2024
SITC 2024: Initial Phase 1C data for vilastobart + atezolizumab presented. 17 patients treated, preliminary responses observed including 1 confirmed PR in liver metastasis patient.
? Stock +15%December 2024
XTX301 Phase 1 Data: Preliminary results showed IL-12 well-tolerated with no DLTs. Sustained IFN-γ signaling without tachyphylaxis. Appointed Caroline Hensley as Chief Legal Officer.
➡️ StableJanuary 2025
Phase 2 Initial Data: Announced 27% ORR in MSS mCRC patients without liver metastases. Responses durable with favorable safety profile (low colitis incidence).
? Stock +20%February 12, 2025
AbbVie Partnership Announced: $52M upfront payment + up to $2.1B in milestones. Collaboration on masked T cell engagers. Announced 3 preclinical programs (PSMA, CLDN18.2, STEAP1).
? Stock +45% (spike to $1.49)March 11, 2025
Q4 2024 Results: Reported financials, cash position $55.3M + $52M AbbVie upfront. Extended runway to Q1 2026. Gilead partnership ongoing for XTX301.
➡️ StableMay 2025 (ASCO)
ASCO 2025 Presentation: Updated Phase 2 data — ORR improved to 26% in 44 patients. Responses lasting up to 37 weeks with significant ctDNA reduction. Low colitis rate (7%).
? Stock +12%June 2025
Follow-On Offering: Raised ~$47M net proceeds ($50M gross). Stock dropped 27% on dilution news. Initiated 150mg Q6W dose cohort enrollment.
? Stock -27% (dropped to $0.78)August 14, 2025
Q2 2025 Results: Revenue $8.1M (vs $2.4M YoY). Net loss $15.8M. Cash $121.6M. Runway extended to end of Q3 2026.
➡️ StableSeptember 2025
Gilead Milestone: Received $17.5M milestone payment for XTX301 development progress. Positive early Phase 1 monotherapy data presented.
? Stock +8%November 6-7, 2025
SITC 2025 Late-Breaking Data: Vilastobart shows 40% ORR in plasma TMB-high MSS mCRC patients without liver metastases — best-in-class result. PSMA development candidate nominated.
? Stock +18%November 13, 2025
Q3 2025 Results: Revenue $19.1M (+745% YoY). Cash $103.8M. Runway extended to Q1 2027. XTX501 IND on track for mid-2026.
➡️ StableNovember 21, 2025
Stock Incentive Plan: Approved 2025 Stock Incentive Plan with one-time stock options repricing to retain talent.
➡️ Stable? CEO: René Russo, Pharm.D.
- Experience: 25+ years in biotech, R&D and commercialization leadership
- Tenure: Since May 2019 (6.4 years)
- Compensation: $1.46M/year (42% salary, 58% stock/bonus)
- Ownership: 0.47% (~$193K in shares)
- Track Record: Led company through IPO (Oct 2021), secured AbbVie & Gilead partnerships, advanced vilastobart from Phase 1 to Phase 2 with improving ORR
? Leadership Team
| Chris Frankenfield | CFO & COO | 2.2 years |
| Katarina Luptakova, M.D. | Chief Medical Officer | 2.1 years |
| Scott Coleman | Chief Development Officer | 2.1 years |
| Caroline Hensley | Chief Legal Officer | Since Dec 2024 |
| Akintunde Bello, Ph.D. | Advisor (ex-BMS/Pfizer) | 25+ years exp. |
? Q3 2025 Financial Results
| Revenue | $19.1M | +745% YoY |
| Net Loss | $16.3M | vs $14M YoY |
| EPS | -$0.11 | vs -$0.22 YoY |
| R&D Expenses | $14.3M | +32% YoY |
? Pipeline Highlights
Vilastobart (XTX101) — anti-CTLA-4 tumor-activated
40% ORR in MSS mCRC (plasma TMB-high, no liver mets) — Phase 2
Partner: Roche (atezolizumab) | ORR improved from 27% → 40% in 12 months
40% ORR in MSS mCRC (plasma TMB-high, no liver mets) — Phase 2
Partner: Roche (atezolizumab) | ORR improved from 27% → 40% in 12 months
XTX301 — IL-12 tumor-activated (Gilead partnership)
Phase 1 — Promising antitumor activity, no DLTs, sustained IFN-γ signaling
Phase 1 — Promising antitumor activity, no DLTs, sustained IFN-γ signaling
XTX501 — PD-1/IL-2 bispecific
IND expected mid-2026 — Novel approach to selective T cell activation
IND expected mid-2026 — Novel approach to selective T cell activation
Masked T Cell Engagers (AbbVie collaboration)
PSMA: Dev candidate nominated Q3 2025 | CLDN18.2: Q4 2025 | STEAP1: H1 2026
INDs expected 2027 | Up to $2.1B potential milestones
PSMA: Dev candidate nominated Q3 2025 | CLDN18.2: Q4 2025 | STEAP1: H1 2026
INDs expected 2027 | Up to $2.1B potential milestones
? Key Partnerships & Funding
| AbbVie | $52M upfront + up to $2.1B milestones | Feb 2025 |
| Gilead (XTX301) | $17.5M milestone received | Sep 2025 |
| Roche | Atezolizumab combination partner | Ongoing |
| Follow-on Offering | $47M net proceeds | Jun 2025 |
? BULL CASE
- 40% ORR exceptional in MSS mCRC — “immunologically cold” tumor with no approved IO options
- ORR trajectory: Improved from 27% (Jan) → 40% (Nov) in 10 months
- Plasma TMB biomarker may identify responders for patient selection
- $103.8M cash — runway to Q1 2027, no near-term dilution risk
- Validated platform: AbbVie ($2.1B potential), Gilead, Roche partnerships
- Consensus target $3.00 (+300% upside from current)
- Experienced CEO with 25+ years, successfully executed multiple partnerships
? BEAR CASE
- Increasing losses ($16.3M vs $14M YoY) despite revenue growth
- Small cohorts — 40% ORR based on limited patient numbers, needs confirmation
- Stock at all-time lows (~$0.75) — market remains skeptical
- June 2025 dilution crushed stock (-27%), may happen again
- Technical indicators predominantly bearish across timeframes
- Partnership dependent — no standalone commercialization capability
- MSS CRC competition — other players advancing in this space
? Analyst Price Targets
| Leerink Partners | Buy | $2.00 |
| Raymond James | Buy | $4.00 |
| Chardan Capital | Strong Buy | $7.00 |
| CONSENSUS | BUY | $3.00 (+300%) |
? Upcoming Catalysts (2025-2027)
- Q4 2025: CLDN18.2 development candidate nomination
- H1 2026: Additional Phase 2 vilastobart data (150mg Q6W dose)
- H1 2026: STEAP1 development candidate nomination
- Mid-2026: XTX501 IND submission
- 2027: INDs for masked T cell engagers (PSMA, CLDN18.2, STEAP1)
- TBD: Potential partnership expansion or acquisition interest
? XILIO THERAPEUTICS (NASDAQ: XLO)
Immuno-Oncologia | Terapie Tumor-Activated | Report Q3 2025
? Analisi Esecutiva
Xilio Therapeutics, Inc. (NASDAQ: XLO) è una società biofarmaceutica in fase clinica che sta sviluppando immunoterapie tumor-activated mascherate — un approccio innovativo progettato per attivare risposte immunitarie esclusivamente all’interno del microambiente tumorale, minimizzando così la tossicità sistemica. Il candidato principale, vilastobart (anticorpo anti-CTLA-4 tumor-activated), ha dimostrato un’eccezionale efficacia clinica con un tasso di risposta obiettiva (ORR) del 40% in pazienti con cancro colorettale metastatico microsatellite-stabile (MSS mCRC) — un’indicazione storicamente difficile da trattare con opzioni immunoterapiche limitate.
Negli ultimi 12 mesi, Xilio ha raggiunto diversi punti di inflessione. Nel febbraio 2025, l’azienda ha assicurato una partnership storica con AbbVie del valore di $52 milioni upfront più fino a $2.1 miliardi in milestone, validando la sua piattaforma di masked T cell engagers. Contemporaneamente, il programma Phase 2 di vilastobart ha mostrato una straordinaria progressione clinica — l’ORR è migliorato dal 27% (gennaio 2025) al 40% (novembre 2025) quando arricchito per pazienti con plasma TMB-high senza metastasi epatiche, posizionando l’asset come potenzialmente best-in-class per questa indicazione.
Highlights Principali:
- 40% ORR in MSS mCRC — 11 su 27 pazienti hanno raggiunto risposta parziale o completa con risposte durature fino a 37 settimane e riduzione significativa del ctDNA
- Profilo di sicurezza favorevole — Solo 7% incidenza di colite vs 20%+ riportato per altri agenti anti-CTLA-4, permettendo miglior tollerabilità
- Partnership $2.1B con AbbVie — Copre 3 programmi di masked T cell engagers (PSMA, CLDN18.2, STEAP1) con finanziamenti significativi non-diluitivi
- Posizione di cassa forte — $103.8M in cassa con runway fino Q1 2027, eliminando rischio di finanziamento a breve termine
- Partnership in espansione — Collaborazione Gilead su XTX301 (IL-12), collaborazione Roche su vilastobart + combinazione atezolizumab
- Crescita ricavi — Q3 2025 ricavi $19.1M (+745% YoY) guidati da milestone partnership da AbbVie e Gilead
Tuttavia, Xilio rimane un biotech alto-rischio, alto-rendimento microcap. Il titolo quota ai minimi storici (~$0.75) nonostante dati clinici convincenti, riflettendo lo scetticismo del mercato riguardo rischi di esecuzione, cash runway oltre il 2027, e dinamiche competitive in immuno-oncologia. L’aumento di capitale di giugno 2025 ha provocato un calo del titolo del 27%, segnalando preoccupazioni per la diluizione. Il target prezzo del consenso degli analisti è di $3.00 (+300%), ma raggiungerlo richiederebbe letture di dati Phase 2 di successo, conseguimento di milestone partnership, e momentum clinico sostenuto attraverso 2026-2027.
Prezzo Attuale: ~$0.75
Target Consenso: $3.00 (+300%)
Cassa in Bilancio: $103.8M
Runway Cassa: Q1 2027
? Timeline 12 Mesi: Eventi Chiave & Catalysts
8 Novembre 2024
SITC 2024: Presentati dati iniziali Phase 1C per vilastobart + atezolizumab. 17 pazienti trattati, risposte preliminari osservate inclusa 1 PR confermata in paziente con metastasi epatiche.
? Azione +15%Dicembre 2024
Dati XTX301 Phase 1: Risultati preliminari mostrano IL-12 ben tollerato senza DLT. Segnale IFN-γ sostenuto senza tachifilassi. Nominata Caroline Hensley come Chief Legal Officer.
➡️ StabileGennaio 2025
Dati Iniziali Phase 2: Annunciato 27% ORR in pazienti MSS mCRC senza metastasi epatiche. Risposte durature con profilo di sicurezza favorevole (bassa incidenza di colite).
? Azione +20%12 Febbraio 2025
Partnership AbbVie Annunciata: $52M upfront + fino a $2.1B in milestones. Collaborazione su masked T cell engagers. Annunciati 3 programmi preclinici (PSMA, CLDN18.2, STEAP1).
? Azione +45% (spike a $1.49)11 Marzo 2025
Risultati Q4 2024: Riportati i finanziari, cassa $55.3M + $52M AbbVie upfront. Runway esteso a Q1 2026. Partnership Gilead in corso per XTX301.
➡️ StabileMaggio 2025 (ASCO)
Presentazione ASCO 2025: Dati Phase 2 aggiornati — ORR migliorato al 26% in 44 pazienti. Risposte durature fino a 37 settimane con riduzione significativa del ctDNA. Tasso colite basso (7%).
? Azione +12%Giugno 2025
Follow-On Offering: Raccolti ~$47M netti ($50M lordi). Azione crollata -27% su notizia di diluizione. Iniziato arruolamento coorte dose 150mg Q6W.
? Azione -27% (scesa a $0.78)14 Agosto 2025
Risultati Q2 2025: Ricavi $8.1M (vs $2.4M YoY). Perdita netta $15.8M. Cassa $121.6M. Runway esteso a fine Q3 2026.
➡️ StabileSettembre 2025
Milestone Gilead: Ricevuto pagamento milestone $17.5M per progressi sviluppo XTX301. Presentati dati positivi early Phase 1 in monoterapia.
? Azione +8%6-7 Novembre 2025
SITC 2025 Late-Breaking Data: Vilastobart mostra 40% ORR in pazienti MSS mCRC plasma TMB-high senza metastasi epatiche — risultato best-in-class. Nominato development candidate PSMA.
? Azione +18%13 Novembre 2025
Risultati Q3 2025: Ricavi $19.1M (+745% YoY). Cassa $103.8M. Runway esteso a Q1 2027. XTX501 IND on track per mid-2026.
➡️ Stabile21 Novembre 2025
Piano Incentivi Azionari: Approvato 2025 Stock Incentive Plan con repricing una tantum delle stock options per trattenere talenti.
➡️ Stabile? CEO: René Russo, Pharm.D.
- Esperienza: 25+ anni nel biotech, leadership in R&D e commercializzazione
- In carica dal: Maggio 2019 (6.4 anni)
- Compenso: $1.46M/anno (42% salario, 58% stock/bonus)
- Ownership: 0.47% (~$193K in azioni)
- Track Record: Ha guidato l’IPO (Ott 2021), ottenuto partnership AbbVie & Gilead, portato vilastobart da Phase 1 a Phase 2 con ORR in miglioramento
? Leadership Team
| Chris Frankenfield | CFO & COO | 2.2 anni |
| Katarina Luptakova, M.D. | Chief Medical Officer | 2.1 anni |
| Scott Coleman | Chief Development Officer | 2.1 anni |
| Caroline Hensley | Chief Legal Officer | Da Dic 2024 |
| Akintunde Bello, Ph.D. | Advisor (ex-BMS/Pfizer) | 25+ anni exp. |
? Risultati Finanziari Q3 2025
| Ricavi | $19.1M | +745% YoY |
| Perdita Netta | $16.3M | vs $14M YoY |
| EPS | -$0.11 | vs -$0.22 YoY |
| Spese R&D | $14.3M | +32% YoY |
? Pipeline Highlights
Vilastobart (XTX101) — anti-CTLA-4 tumor-activated
40% ORR in MSS mCRC (plasma TMB-high, no liver mets) — Phase 2
Partner: Roche (atezolizumab) | ORR migliorato da 27% → 40% in 12 mesi
40% ORR in MSS mCRC (plasma TMB-high, no liver mets) — Phase 2
Partner: Roche (atezolizumab) | ORR migliorato da 27% → 40% in 12 mesi
XTX301 — IL-12 tumor-activated (partnership Gilead)
Phase 1 — Attività antitumorale promettente, no DLT, segnale IFN-γ sostenuto
Phase 1 — Attività antitumorale promettente, no DLT, segnale IFN-γ sostenuto
XTX501 — PD-1/IL-2 bispecifico
IND previsto mid-2026 — Approccio innovativo per attivazione selettiva T cell
IND previsto mid-2026 — Approccio innovativo per attivazione selettiva T cell
Masked T Cell Engagers (collaborazione AbbVie)
PSMA: Dev candidate nominato Q3 2025 | CLDN18.2: Q4 2025 | STEAP1: H1 2026
IND previsti 2027 | Fino a $2.1B milestones potenziali
PSMA: Dev candidate nominato Q3 2025 | CLDN18.2: Q4 2025 | STEAP1: H1 2026
IND previsti 2027 | Fino a $2.1B milestones potenziali
? Partnership Chiave & Finanziamenti
| AbbVie | $52M upfront + fino a $2.1B milestones | Feb 2025 |
| Gilead (XTX301) | $17.5M milestone ricevuto | Set 2025 |
| Roche | Partner combinazione atezolizumab | In corso |
| Follow-on Offering | $47M netti | Giu 2025 |
? BULL CASE
- 40% ORR eccezionale in MSS mCRC — tumore “immunologically cold” senza opzioni IO approvate
- Traiettoria ORR: Migliorato da 27% (Gen) → 40% (Nov) in 10 mesi
- Biomarker plasma TMB può identificare responders per selezione pazienti
- $103.8M cassa — runway fino Q1 2027, no rischio diluizione a breve
- Piattaforma validata: partnership AbbVie ($2.1B potenziali), Gilead, Roche
- Target consenso $3.00 (+300% upside dal prezzo attuale)
- CEO esperto con 25+ anni, ha eseguito con successo multiple partnership
? BEAR CASE
- Perdite in aumento ($16.3M vs $14M YoY) nonostante crescita ricavi
- Coorti piccole — 40% ORR basato su numeri limitati, serve conferma
- Azione ai minimi storici (~$0.75) — mercato scettico
- Diluizione giugno 2025 ha affossato il titolo (-27%), potrebbe ripetersi
- Indicatori tecnici prevalentemente bearish su tutti i timeframe
- Dipendenza da partnership — nessuna capacità di commercializzazione autonoma
- Competizione MSS CRC — altri player avanzano in questo spazio
? Analyst Price Targets
| Leerink Partners | Buy | $2.00 |
| Raymond James | Buy | $4.00 |
| Chardan Capital | Strong Buy | $7.00 |
| CONSENSO | BUY | $3.00 (+300%) |
? Prossimi Catalysts (2025-2027)
- Q4 2025: Development candidate nomination CLDN18.2
- H1 2026: Dati aggiuntivi Phase 2 vilastobart (dose 150mg Q6W)
- H1 2026: Development candidate nomination STEAP1
- Mid-2026: IND submission XTX501
- 2027: IND per masked T cell engagers (PSMA, CLDN18.2, STEAP1)
- TBD: Potenziale espansione partnership o interesse acquisizione